TY - JOUR
T1 - Molecular Pathology of Thymic Epithelial Neoplasms
AU - Kuhn, Elisabetta
AU - Wistuba, Ignacio I.
PY - 2008/6
Y1 - 2008/6
N2 - The etiology and molecular pathogenesis of thymic tumors are unknown. However, during the last two decades there has been some progress on elucidating the genetic abnormalities present and molecular pathways altered in thymic tumors. These abnormalities, while bearing distinctions and similarities to those described in other tumors, can be organized under the "hallmarks of cancer," as proposed by Hanahan and Weinberg. These changes include self-sufficiency in growth signaling, insensitivity to antigrowth signals, ability to evade apoptosis, limitless replicative potential, ability to sustain angiogenesis, and tissue invasion and metastasis. However, this progress is still limited and has not led to better tumor classifications, prognostication of outcome, and design of molecular targeted therapy.
AB - The etiology and molecular pathogenesis of thymic tumors are unknown. However, during the last two decades there has been some progress on elucidating the genetic abnormalities present and molecular pathways altered in thymic tumors. These abnormalities, while bearing distinctions and similarities to those described in other tumors, can be organized under the "hallmarks of cancer," as proposed by Hanahan and Weinberg. These changes include self-sufficiency in growth signaling, insensitivity to antigrowth signals, ability to evade apoptosis, limitless replicative potential, ability to sustain angiogenesis, and tissue invasion and metastasis. However, this progress is still limited and has not led to better tumor classifications, prognostication of outcome, and design of molecular targeted therapy.
UR - http://www.scopus.com/inward/record.url?scp=44249113560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44249113560&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2008.03.007
DO - 10.1016/j.hoc.2008.03.007
M3 - Review article
C2 - 18514126
AN - SCOPUS:44249113560
SN - 0889-8588
VL - 22
SP - 443
EP - 455
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 3
ER -